Clinical trial Olympia-3
A Phase 3, open label, randomized study comparing the efficacy and safety of Odronextamab (REGN1979), an anti-cd20 × anti-cd3 bispecific antibody, in combination with CHOP (O-CHOP) versus rituximab in combination with CHOP (R-CHOP) in previously untreated participants with diffuse large b-cell lymphoma (DLBCL)
| Cancers | |
|---|---|
| Organ | Blood |
| Trial status | Trial open for recruitment |
| Investigator | |
| Trial type |
Interventional with experimental drug
|
| Phase | Trial phase 3 |
| Academic trial | Non |
| Sponsor | Regeneron Pharmaceuticals, Inc. |
| EudraCT Identifier | 2022-502785-25-00 |
| ClinicalTrials.gov | https://clinicaltrials.gov/ct2/show/NCT06091865 |
| Inclusion criteria | 1. Previously untreated participants for CD20+ DLBCL 2. Have measurable disease with at least one nodal lesion with LDi greater than 1.5 cm or atleast one extranodal lesion with LDi greater than 1.0 cm 3. ?18 years 4. ECOG ?2 5. Life expectancy ?12 month |
| Last update |